Last updated: April 22, 2025
Key Findings
Patent AR092500-A1 represents a pharmaceutical composition patent in Argentina, part of a global patent family including US-9326969-B2. The patent covers formulations involving sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, combined with osmotic agents like polyethylene glycol (PEG) for therapeutic use[23][19]. Argentina’s strict patentability guidelines, established in 2012, impose significant barriers to secondary patents, requiring high inventiveness for formulations or dosage regimens[6][9]. Despite this, AR092500’s claims leverage novel combinatory approaches to meet local standards, though enforcement challenges and generic competition persist[2][5].
Legal and Regulatory Framework for Pharmaceutical Patents in Argentina
Patentability Criteria Under Joint Resolution 118/2012
Argentina’s 2012 Guidelines restrict patent grants to inventions demonstrating absolute novelty, inventive step, and industrial applicability[3][9]. Key exclusions include:
- Secondary patents on polymorphs, salts, or formulations of known compounds unless they show unexpected efficacy[6][12].
- Method-of-use claims for existing drugs[22][25].
- Markush-type claims lacking enablement for all variants[6].
AR092500’s claims focus on a fixed-dose combination of empagliflozin with PEG, emphasizing synergistic effects in reducing gastrointestinal side effects compared to prior art[23][19]. This aligns with Argentina’s allowance for compositions demonstrating unpredictable technical advantages[6][9].
Scope and Claims of AR092500
Independent Claim Analysis
-
Claim 1: A pharmaceutical composition comprising empagliflozin (1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)benzyl]benzene) and polyethylene glycol (PEG-3350), wherein the weight ratio of empagliflozin:PEG is 1:50 to 1:200.
- Novelty: Supported by absence of prior art disclosing this specific ratio[19][23].
- Inventive Step: Argues reduced colonic inflammation in diabetic patients, validated by in vivo data[19].
-
Claim 5: Use of the composition in Claim 1 for treating hyperglycemia without inducing diarrhea.
- Exclusion Risk: Method-of-use claims face rejection under Section 7(b) of Argentina’s Patent Law, which bars patents for therapeutic methods[22][25].
Dependent Claims
- Stability enhancements (Claims 2–4): Specify pH ranges (5.0–6.5) and excipients (magnesium stearate) to prevent degradation. These are likely allowable as they solve technical problems (e.g., empagliflozin’s hygroscopicity)[23].
Patent Landscape and Competitive Dynamics
Litigation Risks
- Generic Challenges: Argentina’s National Administration of Medicines, Food, and Medical Technology (ANMAT) has historically permitted generic entry despite pending patents[2][10]. For example, ANMAT approved generic sofosbuvir despite unresolved patent disputes, citing public health imperatives[10].
- Enforcement Gaps: Only one exclusive marketing right (EMR) has been enforced in Argentina due to regulatory ambiguities[2][13].
Market Exclusivity and Expiry
- Term: AR092500 expires in October 2026, contingent on maintenance fee payments[5][11].
- Generic Readiness: At least 15 ANDA applicants have filed for empagliflozin, with tentative approvals indicating imminent entry[5].
Strategic Recommendations
- Portfolio Diversification: File divisional applications focusing on manufacturing processes (e.g., spray-drying PEG-empa mixtures) to circumvent formulation claim rejections[9][12].
- Data Exclusivity Leverage: Submit new clinical data demonstrating AR092500’s superiority in renal-impaired populations, leveraging Argentina’s data protection laws[10][22].
- Litigation Preparedness: Monitor ANMAT’s generic approval patterns and seek preliminary injunctions under Resolution 566/2018, which expedites patent disputes[16][20].
Conclusion
AR092500 navigates Argentina’s restrictive patent landscape through narrowly tailored claims emphasizing technical synergies. However, its commercial viability hinges on overcoming bureaucratic enforcement delays and pre-empting generics via regulatory strategies. The patent’s success will depend on continuous engagement with INPI’s evolving examination practices and proactive litigation measures.
“Argentina’s patent system discourages incremental innovation, favoring generic competition over patent holder rights.” – International Property Rights Index Case Study (2024)[9].
Key Takeaways
- AR092500’s claims are valid under Argentina’s novelty standards but vulnerable to method-of-use exclusions.
- Generic erosion is likely post-2026, necessitating lifecycle management strategies.
- Data exclusivity and process patents offer ancillary protection avenues.
FAQs
-
Can AR092500 withstand a TRIPS compliance challenge?
Yes, but Argentina’s adherence to TRIPS remains inconsistent, particularly in enforcement[9][13].
-
How does Argentina’s inventive step standard compare to the USPTO?
Argentina requires a higher threshold, rejecting "obvious to try" rationales common in the U.S.[6][12].
-
Are pediatric extensions available for AR092500?
No; Argentina does not recognize patent term extensions for pediatric studies[11][22].
-
What is the typical INPI examination timeline?
4–5 years, with frequent office actions disputing secondary patent claims[11][20].
-
How do Argentine courts handle Hatch-Waxman-like disputes?
No statutory linkage exists; litigation occurs post-generic approval, often favoring generics[2][10].
Sources Cited
[1][2][3][5][6][9][10][11][12][13][19][20][22][23][25]
References
- https://www.drugpatentwatch.com/p/generic-entry-opportunity-date/Argentina
- https://riker.com/publications/patent-protection-in-argentina/
- https://atr-ipri24.s3.amazonaws.com/case-studies/IPRI_Case_Study_Argentina_2024_v2.pdf
- https://www.miranda-argentina.com/patents/
- https://www.drugpatentwatch.com/p/tradename/JARDIANCE
- http://www.rivistaodc.eu/argentina-guidelines-examination-chemical-pharmaceutical
- https://atr-ipri24.s3.amazonaws.com/case-studies/IPRI_Case_Study_Argentina_2024_v2.pdf
- https://www.miranda-argentina.com/wp-content/uploads/2016/12/ARGENTINA-PATENT-AND-UTILITY-MODEL-LAW-1.pdf
- https://atr-ipri24.s3.amazonaws.com/case-studies/IPRI_Case_Study_Argentina_2024_v2.pdf
- https://makemedicinesaffordable.org/argentina-civil-society-launch-campaign-big-pharma-drop-the-case/
- https://www.ip-coster.com/IPGuides/patent-pct-argentina
- https://www.columbia.edu/~bns3/data/secondaryrp.pdf
- https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds171_e.htm
- https://patentscope.wipo.int/search/en/advancedSearch.jsf
- https://atr-ipri24.s3.amazonaws.com/case-studies/IPRI_Case_Study_Argentina_2024_v2.pdf
- https://www.argentina.gob.ar/inpi
- https://portaltramites.inpi.gob.ar/marcasconsultas/busqueda
- https://www.wipo.int/directory/en/contact.jsp?country_id=8&type=ADMIN_IP
- https://pubchem.ncbi.nlm.nih.gov/patent/US-9326969-B2
- https://www.argentina.gob.ar/inpi/patentes-de-invencion-y-modelos-de-utilidad
- https://www.uaipit.com/uploads/publicaciones/files/0000001438_20%20Ley%20de%20Patente%20Argentina.pdf
- http://servicios.infoleg.gob.ar/infolegInternet/anexos/35000-39999/35001/texact.htm
- https://pubchem.ncbi.nlm.nih.gov/patent/US-9326969-B2
- https://www.argentina.gob.ar/inpi/patentes-de-invencion-y-modelos-de-utilidad
- https://www.uaipit.com/uploads/publicaciones/files/0000001438_20%20Ley%20de%20Patente%20Argentina.pdf
- http://servicios.infoleg.gob.ar/infolegInternet/anexos/35000-39999/35001/texact.htm
